AGTC News and Press, Applied Genetic Technologies Corporation From 06/16/20

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Bionic Sight, LLC announced today that it has dosed the first patient in the Company’s Phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with Retinitis Pigmentosa. This is an important step toward bringing BS01 forw...

Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19 pandemic GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies C...

Applied Genetic Reports Positive Preclinical Data for Eye Disorder Treatment Applied Genetic Technologies Corporation (AGTC) announced the results for its clinical trial related to X-Linked retinitis pigmentosa. The data provided the basis for determining the starting dose and the vector...

Applied Genetic Technologies ( AGTC +4.0% ) announces the publication in Human Gene Therapy of preclinical data supporting the rationale of the vector it is using in its gene therapy for patients with X-linked retinitis pigmentosa (XLRP), an inherited disorder characterized by progre...

 -   Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - GAINESVILLE...

Applied Genetic Technologies Corporation (AGTC) Q3 2020 Results Conference Call May 13, 2020 08:00 AM ET Company Participants Sue Washer - CEO Matt Feinsod - EVP of Global Strategy and Development Mark Shearman - CSO Bill Sullivan - CFO Conference Call Participants Jim...

The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with their 2020 Q3 earnings Read more ...

Applied Genetic (NASDAQ: AGTC ): Q3 GAAP EPS of -$0.50 beats by $0.05 . More news on: Applied Genetic Technologies Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date - - Company to host conference call and webcast today at 8:00am ET - ...